New insights in oncogenic alterations in clear-cell renal cell carcinoma with sarcomatoid dedifferentiation

Date

09 Oct 2016

Session

Poster display

Presenters

Ronan Flippot

Citation

Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373

Authors

R. Flippot1, G.G. Malouf2, E. Comperat3, X. Su4, R. Mouawad2, M. Roupret5, J. Spano2, D. Khayat2

Author affiliations

  • 1 Medical Oncology, Groupe Hospitalier Pitié Salpetriere, 75013 - Paris/FR
  • 2 Medical Oncology, Groupe Hospitalier Pitié Salpetriere, Paris/FR
  • 3 Pathology, Groupe Hospitalier Pitié Salpetriere, Paris/FR
  • 4 Bioinformatics And Computational Biology, MD Anderson Cancer Center, Houston/US
  • 5 Urology, Groupe Hospitalier Pitié Salpetriere, Paris/FR
More

Resources

Background

Sarcomatoid dedifferentiation in renal cell carcinoma (sRCC) has been associated with aggressive disease and poor outcome. However, the molecular landscape of sRCC remains largely unknown, notably regarding chromatin remodeling genes alterations and the alterations of wild-type VHL tumors.

Methods

Sixteen primary sRCCs and matched normal tissues underwent whole-exome sequencing, with a median coverage of 110x and 50x for cancer and normal samples, respectively. These data were compared to 417 non-sarcomatoid RCCs from the Cancer Genome Atlas RCC data set. Associations with clinical and pathological tumor features were performed.

Results

Most frequent somatic mutations included VHL (11/16, 69%), and chromatin remodeling genes PBRM1 (7/16, 44%) and SETD2 (3/16, 19%). BAP1 mutations were only present in 2 cases (12%). These alterations of chromatin remodeling genes were not enriched compared to the TCGA cohort of clear-cell RCC. Of note, chromatin remodeling genes alterations were not mutually exclusive, with concurrent mutations of PBRM1 and BAP1, and PBRM1 and KDM5C reported in one and two patients, respectively. No recurrent alterations of known oncogenic pathways such as MAPK, PIK3Ca/mTOR, p53 or tumor metabolism were reported. Out of 5 patients (31%) without VHL alterations, 2 (40%) had a metastatic evolution compared to only 18% in patients with VHL mutations. All had at least one alteration of chromatin remodeling genes including BAP1, PBRM1 and SMARCA4. Interestingly, mutational load was not correlated with clinical and pathological tumor features such as Fuhrman grade and TNM stage, nor with alterations of known described oncogenes.

Conclusions

The genetic landscape of sRCC of clear-cell type might not be different from other clear-cell RCC. Patients with wild-type VHL tumors represent nearly one third of those cancers, had more aggressive tumors and constant chromatin remodeling gene alterations. These data underline the urgent need for the characterization of epigenetic modifications that might further explain the distinctive features of sRCC.

Clinical trial identification

Legal entity responsible for the study

Assistance Publique - Hôpitaux de Paris Fondation AVEC

Funding

Fondation AVEC

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings